Siemens stays in Russia as parent co exits
To view this email as a web page, click here

Today's Rundown

Featured Story

Nonprofit systems Advocate Aurora Health, Atrium Health announce $27B, 67-hospital merger

Under the new brand of Advocate Health, the joint system would serve about 5.5 million patients, operate over 1,000 care sites and employ 148,000 people.

read more

Top Stories

CSL's $11.7B Vifor buy, 2021's biggest biopharma M&A deal, hits antitrust delay

Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected. Vifor said some antitrust authorities haven’t delivered a verdict.

read more

As Siemens AG leaves Russia over Ukraine war, Siemens Healthineers will stay

Siemens AG’s decision to exit Russia does not include Siemens Healthineers, according to the company, which previously said it would continue to support healthcare providers and patients in the country.

read more

Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race

Bristol Myers Squibb came to the rescue of a beleaguered BridgeBio today, striking a $905 million biobuck deal to secure a rival to oncology candidates in development at Merck, Novartis, Roche, Sanofi and more.

read more

AMA, AHA among groups pressing HHS to keep COVID-19 emergency past July expiration date

Major provider groups are pressing HHS to continue the COVID-19 public health emergency, which could expire in July and erase key regulatory flexibilities for doctors and hospitals.

read more

Pfizer partner Biovac warns of production slump amid low COVID vaccine demand: report

Following similar proclamations from the Serum Institute of India and Aspen Pharmacare, Pfizer-partnered Biovac is the latest pandemic vaccine manufacturer to forecast possible production shortfalls amid a slump in global demand.

read more

Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results

At Caribou Biosciences’ upcoming 10th birthday party celebration, the chardonnay will be flowing. That’s because the biotech is uncorking first-in-human data for its CAR-T cell therapy that CEO Rachel Haurwitz believes are better than the three approved lymphoma treatments in the class.

read more

GE Healthcare aims to bring prenatal ultrasound to the home, with investment in smartphone-scanner developer

Pulsenmore’s device docks with a smartphone, allowing women to conduct their own exams and potentially skip an in-person doctor’s visit.

read more

Ready to go to FDA, can Hengrui's China-made PD-1 liver cancer immunotherapy change the tides?

After two FDA rejections against China-made cancer immunotherapies this year, another Chinese pharma major hopes it has the data to crack the agency’s doors open in liver cancer. But one major uncertainty remains.

read more

Witty: UnitedHealth bullish on its growth trajectory, particularly for Optum

Executives said Wednesday at the BofA Securities Healthcare Conference that they're confident that the company will continue to meet its double-digit growth targets even as it continues to expand.

read more

Paige nets European OK for AI to spot prostate cancer biomarkers

With the new tool, Paige is aiming to make biomarker detection more accessible and more widely used in cancer diagnostics.

read more

Human Cell Atlas initiative makes strides as scientists piece together 'Google Map' of human cells

The Human Cell Atlas consortium has added important pieces to the creation of the full map of human cells, offering new insights into gene activity in specific cell types and how immune cells behave in various human tissues and organs.

read more

Mammogram-reading AI developer Therapixel snags €15M to expand US presence

To make MammoScreen more ubiquitous in cancer screening across the U.S., Therapixel plans to add new features and ramp up its sales and commercial activities in the region.

read more